Clinical Trial Update: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

This is a Phase 2 study evaluating intensity-modulated total marrow irradiation added to fludarabine/busulfan conditioning for allogeneic transplantation in hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: ACTIVE_NOT_RECRUITING